Investors like the idea of Allergan selling two small units, having a laser focus on core areas

CEO Brent Saunders said the drug giant will use proceeds to buy back shares, cautioning ‘there is no fire sale’
A woman getting Botox treatment
Shares in Allergan bounced Wednesday on the news and were up slightly

Dublin-based drug giant Allergan PLC (NYSE:AGN) is exploring the sale of two relatively small businesses, in a bid to reassure investors and breathe new life into its sagging shares.

At first blush, investors appear to be buying into the idea of the company consolidating its business. Shares in Allergan bounced Wednesday on the news and were trading about 0.7% higher to US$152.10.

Allergan shares have lost more than half their value since peaking in July 2015 and have fallen about 13% this year.

CEO Brent Saunders said the pharmaceutical giant will use the proceeds from the sale to reduce debt and buy back shares, cautioning ‘there is no fire sale.’

READ: Allergan 1Q tops analyst estimates as pharma giant raises full-year guidance

The drug giant is pursuing a sale of its women's health and infectious diseases businesses after wrapping up its strategic review earlier this year which even weighed in on more drastic options like splitting the company or making acquisitions to boost its sagging stock price.

"There is no fire sale at Allergan," Saunders told the Bernstein Strategic Decisions Conference in New York. "There is no undue pressure to sell them for a bargain basement price."

Saunders said that after the sales, the company would focus on four core businesses: medical aesthetic products such as Botox, central nervous system treatments, eye care and gastrointestinal products.

"We have a very strong pipeline in all those areas. Having a focus on those four areas will make Allergan a more exciting company," Saunders told Reuters in an interview.

Saunders said the decision by the board to shed just those two businesses was unanimous.

View full AGN profile View Profile

Allergan Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.